Venetoclax-rituximab holds substantial promise in CLL
- PMID: 29651129
- DOI: 10.1038/s41571-018-0017-z
Venetoclax-rituximab holds substantial promise in CLL
Comment on
-
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976. N Engl J Med. 2018. PMID: 29562156 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
